Instem (INS) Share Price, News & Analysis

Company Overview

Instem plc, together with its subsidiaries, provides information technology solutions and services to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution. The company also offers computational toxicology products and services; Blur Clinical Annonymization; Logbook ELN, a repository for information; Morphit for discovery data visualization; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a windows-based system for non-clinical evaluation studies. In addition, it provides Samarind RMS to manage medical product information; submit platform that offers tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; SENDView, an application that simplifies the review of SEND datasets; KnowledgeScan Target Safety Assessment services; SENDTrial, a web based solution that can be accessed through a subscription; and Predict delivers computational models. Further, the company provides Sorcerer Colony Counter; sales and administrative support; training, validation, consultancy, cloud, and safety assessment and regulatory information management software services; software solutions to extract intelligence from research and development related healthcare data; and holds intellectual property rights and investment. It also develops, manufactures, and supplies software and hardware products for in vitro study data collection and management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: 830 to 830
• 52-Week Range: N/A
• Volume: 3,800 shs
• Average Volume: 85,542 shs
• Market Capitalization: £199.62 million
• P/E Ratio: 5,928.57
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

INS Stock Analysis - Frequently Asked Questions

How do I buy shares of Instem?

Shares of INS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Instem own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Instem investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), IQE (IQE) and Omega Diagnostics Group (ODX).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: LON:INS
• CIK: N/A
• Web: www.instem.com
• Phone: +44-1785-825600
• Fax: N/A
• Employees: 500
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX 0.14
• Trailing P/E Ratio: 5,928.57
• Forward P/E Ratio: N/A
• P/E Growth: 1.89
• Net Income: £3.34 million
• Net Margins: 5.50%
• Pretax Margin: N/A
• Return on Equity: 6.35%
• Return on Assets: 4.62%

Debt

• Debt-to-Equity Ratio: 3.47
• Current Ratio: 0.95
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: £61.63 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 15.25
• Book Value: GBX 239 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 24,050,000
• Free Float: N/A
• Market Cap: £199.62 million
• Optionable: Not Optionable
• Beta: 0.42